BioGene Therapeutics Appoints 30-Year Industry Veteran Ty Howton to Board
SRPT•BioGene Therapeutics has appointed Ty Howton to its board of directors effective immediately, leveraging his nearly 30 years of biopharmaceutical leadership. Howton’s experience includes executive roles at Vertex, Sarepta and Solid Biosciences, where he drove multiple equity financings and advanced gene therapy candidates into clinical trials.
1. Appointment of Ty Howton
BioGene Therapeutics has added Ty Howton to its board of directors effective immediately, expanding its governance team with a seasoned biopharmaceutical executive. This move enhances the company’s oversight as it progresses its research and development efforts.
2. Proven Industry Track Record
Howton brings almost 30 years of leadership experience, including executive roles at Vertex Pharmaceuticals, Sarepta Therapeutics and Solid Biosciences. He facilitated multiple series-stage equity financings, non-dilutive arrangements and debt facilities, while advancing gene therapy candidates into clinical trials and building operational infrastructure at organizations with under 150 employees.
